Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) traded down 36% during trading on Wednesday . The stock traded as low as $3.20 and last traded at $3.55. 4,146,200 shares traded hands during trading, an increase of 262% from the average session volume of 1,146,000 shares. The stock had previously closed at $5.55.
Several analysts recently commented on the company. Zacks Investment Research raised Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald set a $13.00 price target on Axsome Therapeutics and gave the company a “buy” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $16.90.
The firm has a market cap of $87.16 and a price-to-earnings ratio of -2.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.86 and a current ratio of 3.86.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.com-unik.info/2018/01/10/axsome-therapeutics-axsm-shares-down-36.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
What are top analysts saying about Axsome Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axsome Therapeutics and related companies.